筋肉注射で使用される持効性ハロペリドール使用中に発生した悪性症候群の1例

  • 山口 充
    埼玉医科大学総合医療センター高度救命救急センター
  • 間藤 卓
    埼玉医科大学総合医療センター高度救命救急センター
  • 井口 浩一
    埼玉医科大学総合医療センター高度救命救急センター
  • 上村 直子
    埼玉医科大学総合医療センター高度救命救急センター
  • 志賀 元
    埼玉医科大学総合医療センター高度救命救急センター
  • 森脇 龍太郎
    埼玉医科大学総合医療センター高度救命救急センター
  • 堤 晴彦
    埼玉医科大学総合医療センター高度救命救急センター

書誌事項

タイトル別名
  • Neuroleptic Malignant Syndrome Caused by Haloperidol Decanoate.

この論文をさがす

抄録

Neuroleptic malignant syndrome (NMS) occurs suddenly in patients treated with neuroleptic agents and involves high mortality. We report a case of NMS due to intramuscular injection of haloperidol decanoate. A 29-year-old man with paranoia schizophrenia since the age of 19 years was treated with neuroleptics. From 4 months ago, he was treated with haloperidol decanoate (50mg i.m. monthly), increased to 100mg/month. On the day before admission, he took an overdose of neuroleptics (include chlorpromazine hydrochloride 4.2g). He was transfered to our hospital due to drug intoxication. After admission, he developed NMS. After onset, haloperidol decanoate and all other neuroleptics were stopped. He was treated with dantrolene, bromocriptine, muscle relaxants, and intensive care including assisted ventilation, but his clinical condition and laboratory data did not improved for 25 days. In this case, we studied drug concentration in muscles undergoing haloperidol decanoate injection to determine the possible muscle resection for decreasing the blood concentration of the drug, but the patient recovered without muscle resection.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (13)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ